A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases

Trial Profile

A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Icotinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Beta Pharma
  • Most Recent Events

    • 14 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 14 Jul 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
    • 29 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top